Dr. Dickler on MONARCH 1 Results in HR+/HER2- Breast Cancer

Name: Dr. Dickler on MONARCH 1 Results in HR+/HER2- Breast Cancer
Uploaded: 2016-06-07T21:39:13.000Z
Description: Maura N. Dickler, MD, Memorial Sloan Kettering Cancer Center, discusses the results of the single-arm MONARCH 1 trial, which examined the efficacy of the CDK4/6 inhibitor abemaciclib in heavily pretreated patients with refractory, hormone-receptor (HR)–positive, HER2-negative advanced breast cancer.

June 7, 2016

Maura N. Dickler, MD

Video

Conference|ASCO Annual Meeting

Maura N. Dickler, MD, Memorial Sloan Kettering Cancer Center, discusses the results of the single-arm MONARCH 1 trial, which examined the efficacy of the CDK4/6 inhibitor abemaciclib in heavily pretreated patients with refractory, hormone-receptor (HR)–positive, HER2-negative advanced breast cancer.

<<<